News

Aastrom intends to initiate Phase 3 clinical testing of its treatment for CLI in early 2011. Aastrom said that the designation may allow it to submit portions of

Altomari, a former senior manager at Johnson & Johnson, has been serving as Agile’s executive chairman. He will succeed Thomas Rossi, who joined Agile as president and CEO

Diamyd claims that NP2 Enkephalin is the first drug candidate from its proprietary NTDDS (Nerve Targeting Drug Delivery System)platform focally delivering therapeutic compounds directly to the nervous system.

Synairgen said that upon issuance, the patented claims will provide the company with patent protection for the use of its drug in the elderly population. Synairgen CEO Richard

Furthermore, Health Canada has advised that an inspection for the issue of an Establishment License has been scheduled over a number of days commencing 29 November 2010, following

PillCam Express is a video capsule delivery device for patients who are unable to ingest the capsule or who have slow gastric emptying times PillCam SB 2-EX is

Astellas Pharma is also expected to transfer the manufacturing and marketing approval for all Intal products to Sanofi-aventis as of 1 October 2010. Intal is a chemical mediator

The Veeva CRM suite of applications includes VBioPharma, VMobile and VInsights. VBioPharma offers multiple editions in one CRM product to accommodate the unique needs of various life sciences

The pre-development agreement provides MorphoSys with an option to enter into a formal co-development for the respective program with Novartis. MorphoSys and Novartis entered into a strategic collaboration